Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.
Market Dynamics
Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.
Key features of the study:
- This report provides in-depth analysis of the global viral vector and plasmid DNA manufacturing market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market
Detailed Segmentation:
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Region:
- North America
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- Latin America
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- Connected
- Regular Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Lonza Group AG *
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- FinVector Vision Therapies
- Cobra Biologics and Pharmaceutical Services
- Sigma-Aldrich Co. LLC
- VGXI, Inc.
- VIROVEK
- SIRION Biotech GmbH
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Sanofi
- Cell and Gene Therapy Catapult
- Brammer Bio
- MassBiologics
“*” marked represents similar segmentation in other categories in the respective section.
